PT  - JOURNAL ARTICLE
AU  - Sumowski, James F.
AU  - Sandry, Joshua
TI  - Multiple Sclerosis Cognitive Scale (MSCS): A Brief Psychometrically-Robust Metric of Patient-Reported Cognitive Difficulty
AID  - 10.1101/2024.04.29.24306587
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.29.24306587
4099  - http://medrxiv.org/content/early/2024/05/01/2024.04.29.24306587.short
4100  - http://medrxiv.org/content/early/2024/05/01/2024.04.29.24306587.full
AB  - Background Cognitive decline is common in multiple sclerosis (MS), but existing metrics of patient-reported cognitive difficulties are lengthy, lack psychometric rigor, and/or fail to query expressive language deficits prevalent in MS.Objective To develop the Multiple Sclerosis Cognitive Scale (MSCS) as a brief psychometrically-robust metric of patient-reported cognitive deficits.Method Exploratory factor analysis (EFA) was conducted on 20 items of the Perceived Deficits Questionnaire (PDQ) plus five newly developed language questions in a large sample of patients with MS and matched respondents without neurologic disease. Confirmatory principal components analysis (PCA) in an independent sample assessed the EFA factor structure. Reliability of the new scale and subscales was assessed, and we evaluated the relationship between the new scale and objective cognitive impairment.Results EFA in patients (n=502) and controls (n=350), item analyses, and confirmatory PCA in an independent sample of patients (n=361) and controls (n=150) supported construction of an eight-item scale with four 2-item subscales assessing Executive / Speed, Working Memory, Expressive Language, and Episodic Memory. Internal consistency was excellent for the total MSCS (α=0.93) and good for each subscale (Executive / Speed, α=0.85; Working Memory, α=0.83, Expressive Language, α=0.87; Episodic Memory, α=0.85). There was a medium-sized relationship between objective cognitive impairment and MSCS scores (η2 [95%CI] = 0.06 [0.01, 0.13], but cognitive impairment was not related to the traditional PDQ (0.01 [0.00, 0.06]).Conclusion The MSCS is supported as a brief, psychometrically-robust, reliable, and valid metric of patient-reported cognitive deficits in MS. The MSCS holds promise for improving assessment of MS cognitive dysfunction in clinical and research settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded in part by the National Institute of Child Health and Development (NICHD) within the National Institutes of Health (NIH; R01 HD082176 to JFS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Icahn School of Medicine at Mount Sinai gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors